Breakthrough, Standalone Liquid Biopsy Urine Test for Prostate Cancer

The miR Sentinel™ Test is the only standalone, non-invasive liquid biopsy urine test that accurately detects, classifies and monitors prostate cancer at the molecular level with 95% Sensitivity and Specificity.

Learn More

Actionable Answers To The Most Important Questions

The miR Scientific Disease Management Platform™ is transforming cancer management by delivering actionable and accurate results to physicians and patients from a single urine sample, answering the three most important questions:

Is cancer present? How severe is it? What’s next?

Get Your Answers
New Prostate Cancer Cases Are Diagnosed Globally Every Year
Survival Rate With Early-Stage Diagnosis

The miR Scientific Sentinel® Test Provides One Of Four Results

No Cancer

Our technology identifies molecular evidence of malignancies from the entire prostate gland, even in early onset of the disease, so if the test shows that cancer is not present, patients and physicians can confidently conclude that no cancer is present at the time of diagnosis.  No means No.

Yes Cancer/Intermediate Risk

Depending on the risk tolerance of patients and physicians, they may decide on monitoring the disease for progression non-invasively under an active surveillance protocol or elect to undergo a definitive treatment.

Yes Cancer/Low Risk

An overwhelming majority of prostate cancer patients have an indolent, or clinically insignificant localized cancer that does not require a definitive treatment.  For patients with low risk classifications, a physician may recommend a follow up under an active surveillance protocol, which for patients simply entails providing more urine samples periodically to ensure the disease has not progressed.

Yes Cancer/High Risk

Patients whose molecular signature indicates the presence of high grade disease typically would undergo interventional definitive treatment, the specifics of which will be determined by the specialist care provider. Our technology identifies molecular evidence of the malignancies from the entire prostate gland, even in early onset of the disease.  Yes means Yes and No means NO.

Uniquely miR


Accelerate the right diagnosis and treatment for individual cancer management with accurate diagnosis, classification, and monitoring.


Help patients avoid the invasive, inaccurate, and painful diagnostic procedures that are the current standard of care. miR delivers results with zero contact.


Broaden access to life-saving cancer screening with a completely standalone urine test that diagnoses and classifies prostate cancer with no additional testing requirements.


The miR Disease Management Platform™ is peer-reviewed and validated for the screening and classification of prostate cancer.


Rapid turnaround of reliable information guides treatment decisions and enables true cost-effectiveness in prostate cancer screening and management.


Unlike biopsies, MRIs, and other current options, the miR platform is high-throughput, easily administered, and cost-effective for large volumes of patients.

Why It Matters

Prostate cancer is prevalent and deadly.

It represents the highest number of new cancer cases diagnosed annually and is the second leading cause of cancer deaths among men. Early detection and the ability to identify high grade disease early are key to effective disease management.  

Unlike other cancers, most prostate cancers are indolent and are unlikely to ever need treatment, and only a relatively small number of prostate cancer patients have aggressive disease that requires intervention.

The challenge lies in effectively differentiating between the two, quickly, but until now, no effective, accurate and non-invasive tests have been developed for the early detection and grade classification of prostate cancer.

Today’s Standard Of Care Is Ineffective

Biopsy Reliant

The current standard of care relies on PSA (Prostate Specific Antigen) and Digital Rectal Exams (DRE) to trigger core needle biopsies for the detection and diagnosis of prostate cancer.

Unnecessary Pain

It is inaccurate, invasive and often results in overtreatment.  70% of diagnostic core needle biopsies are unnecessary and consequently incur cost and morbidities.

Preserving Avoidance

The ineffectiveness of today’s standard of care leads many men to completely avoid the screening process. It is estimated that over 60% of age-eligible men remain unscreened.

Current Standards Are Failing Patients, Physicians, Health Systems, And Payors.


Today’s Standard

Invasive, expensive and inaccurate with 44% Sensitivity

Primary Care Visit

Urologist Visit

Multiple Digital Rectal Exams

Multiple PSA Blood Tests

1 or More Prostate Biopsies

The New Standard

Easily Administered, Pain-Free, Accurate, Non-Invasive, with 95% Sensitivity and Specificity

1 Urine Sample

Learn more about miR Scientific’s liquid biopsy urine test and the breakthrough accuracy of our sncRNA testing techniques and proprietary scoring algorithm.

Everyone Benefits

Our non-invasive, pain-free prostate cancer diagnostic testing and monitoring platform helps healthcare providers, patients, and employers realize true cost-effectiveness and efficiency in prostate cancer screening and management for the first time.


Leverage the most accurate prostate cancer decision-making platform to identify and rapidly treat patients with the greatest need.


Experience a non-invasive, accurate, accessible prostate cancer test that delivers clear results to you and your doctor with a single urine specimen.


Keep your employees and their families healthy and reduce excessive urologic cancer screening, treatment costs and unproductive workdays with a straightforward, validated and highly accessible urine test.

miR Solution

A Novel, Proprietary Test with Breakthrough Results

Our molecular diagnostic capabilities are a novel approach to cancer detection, classification, and monitoring, using advanced sncRNA interrogation techniques, a proprietary scoring algorithm and innovative clinical decision support tools.

miR’s technology isolates pre-classified, informative RNA entities from urinary exosomes, and uses proprietary tools to detect and process signals from numerous RNA entities that are evident in the specimens.

Learn More

Making Healthcare History

miR Scientific’s Sentinel™ test is healthcare’s first and only truly standalone urine test that diagnoses and classifies prostate cancers with 95% Sensitivity and Specificity—no rectal exam, blood test, biopsy nor strict urine requirements.

miR’s test provides the most comprehensive prostate cancer surveillance and clinical decision-making tool across the continuum of cancer care.

Learn More

When It Comes To Cancer, Do You Want More Questions Or More Answers?

Avoid the inaccurate blood tests and painful biopsies and get complete cancer diagnosis and classification information from one urine sample.

Contact miR